Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

INCYTE CORPORATION

(INCY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/02/2020 04/03/2020 04/06/2020 04/07/2020 04/08/2020 Date
77.07(c) 78.59(c) 85.11(c) 86.66(c) 87.75(c) Last
1 513 547 2 222 256 3 234 069 2 971 522 2 082 441 Volume
+3.90% +1.97% +8.30% +1.82% +1.26% Change
More quotes
Financials (USD)
Sales 2020 2 417 M
EBIT 2020 412 M
Net income 2020 313 M
Finance 2020 2 365 M
Yield 2020 -
Sales 2021 2 808 M
EBIT 2021 743 M
Net income 2021 657 M
Finance 2021 3 087 M
Yield 2021 -
P/E ratio 2020 65,4x
P/E ratio 2021 29,7x
EV / Sales2020 6,89x
EV / Sales2021 5,68x
Capitalization 19 022 M
More Financials
Company
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (82.2%); - royalties (14.2%); - income from research and... 
More about the company
Surperformance© ratings of Incyte Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on INCYTE CORPORATION
04/05INCYTE : Announces First Presentation of Phase 3 Data from the TRuE-AD Program o..
BU
04/02INCYTE : Announces Plans to Initiate a Phase 3 Clinical Trial of Ruxolitinib (Ja..
BU
03/26INCYTE CORP : Change in Directors or Principal Officers (form 8-K)
AQ
03/26INCYTE : Names New Member to Its Board of Directors
BU
03/26INCYTE CORPORATION : Nomination
CO
03/24INCYTE : Data from Phase 3 TRuE-AD Trials of Ruxolitinib Cream in Atopic Dermati..
BU
03/16ELI LILLY, INCYTE : Baricitinib Gets FDA Breakthrough Designation in Alopecia Ar..
DJ
03/11INCYTE CORPORATION : Report
CO
03/05INCYTE : MorphoSys Resolves a Capital Increase to Implement the Purchase of 3,62..
AQ
03/04INCYTE : MorphoSys and Incyte Announce Antitrust Clearance of Global Collaborati..
AQ
03/03FDA Accepts MorphoSys Biologics License Application and Grants Priority Revie..
AQ
02/27INCYTE : Partners with Artist and Patient J.G. Jones to Raise Awareness for Myel..
BU
02/21INCYTE CORPORATION : Report
CO
02/19INCYTE : Announces Launch of the Incyte : Ingenuity Award Program to Recognize I..
BU
02/19INCYTE : Announces Positive Topline Results From Phase 3 TRuE-AD Program Evaluat..
BU
More news
News in other languages on INCYTE CORPORATION
04/03Novartis prévoit de tester son Jakavi sur des patients Covid-19
04/03INCYTE : Novartis-Medikament soll Coronavirus-Patienten Intensivstation ersparen
04/03Novartis prévoit de tester son Jakavi sur des patients Covid-19
03/09MORPHOSYS IM FOKUS : Fortschritte beim Hoffnungsträge Tafasitamab
03/09Wall Street : sauve in extremis un gain hebdo, pétrole -10%
More news
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | INCY | US45337C1027 | MarketScreener
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 91,32  $
Last Close Price 87,75  $
Spread / Highest target 41,3%
Spread / Average Target 4,06%
Spread / Lowest Target -15,7%
EPS Revisions
Managers
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
Christiana Stamoulis Chief Financial Officer & Executive Vice President
Steven H. Stein Chief Medical Officer & Executive Vice President
Dashyant Dhanak Chief Scientific Officer & Executive VP
Paul Alan Brooke Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION-0.76%18 786
LONZA GROUP14.61%30 981
CELLTRION, INC.0.72%23 150
IQVIA HOLDINGS INC.-22.54%23 076
SEATTLE GENETICS, INC.6.66%21 035
GALAPAGOS NV-3.49%12 707